1-20 of 325268
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation

Available to Purchase
Marion Falabrègue, Candice Aurrand, Léa Cazaulon, Nadia Boussetta, Sara Zumerle, Zoubida Karim, Nouzha Djebrani-Oussedik, Joel POUPON, Sandra Guilmeau, Emeric Dupe, Anne Aucouturier, Philippe Langella, Luis G Bermudez-Humaran, Sophie Vaulont, Carole Peyssonnaux
Journal: Blood
Blood blood.2025028370.
https://doi.org/10.1182/blood.2025028370
Published: 2025
Includes: Supplemental data
Journal Articles

Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)

Available to Purchase
Clinical Trials & Observations
Terri Parker, Adam Landon Rosenthal, Vaishali Sanchorawala, Heather J Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius K. Girnius, Patrick Hagen, Emma C Scott, Antje Hoering, Brian G.M. Durie, Robert Z Orlowski
Journal: Blood
Blood blood.2024027962.
https://doi.org/10.1182/blood.2024027962
Published: 2025
Journal Articles

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy

Open Access
Tiziana Bruno, Maria Chiara Cappelletto, Clelia Cortile, Stefano Di Giovenale, Bruno Amadio, Francesca De Nicola, Italia Falcone, Stefano Giuliani, Belinda Palermo, Valeria Catena, Ludovica Ciuffreda, Fulvia Cerruti, Paolo Cascio, Roberta Merola, Serena Masi, Valentina De Pascale, Ombretta Annibali, Silvia Ferraro, +39, Svitlana Gumenyuk, Francesco Pisani, Francesco Marchesi, Andrea Mengarelli, Maurizio Fanciulli, Giacomo Corleone
Journal: Blood
Blood blood.2025028441.
https://doi.org/10.1182/blood.2025028441
Published: 2025
Includes: Supplemental data
Journal Articles

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Open Access
Clinical Trials & Observations
Lorenzo Falchi, Anna Sureda, Sirpa Leppä, Joost SP Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W Merryman, Pieternella J. Lugtenburg, Pau Abrisqueta, Kim Linton, Gauri Sunkersett, Daniela Hoehn, Ali Rana, Aqeel Abbas, Jennifer Marek, Yi Hao, Andrew J Steele, Christopher Morehouse, Martin Hutchings, David Belada
Journal: Blood
Blood blood.2025029909.
https://doi.org/10.1182/blood.2025029909
Published: 2025
Includes: Supplemental data
Journal Articles

CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell-intrinsic inflammatory pathways

Available to Purchase
Tanner C Martinez, Matthew R. M. Jotte, Saira Khan, Angela Stoddart, Hunter Z. Blaylock, Ankit Malik, Megan E. McNerney
Journal: Blood
Blood blood.2024026815.
https://doi.org/10.1182/blood.2024026815
Published: 2025
Includes: Supplemental data
Journal Articles

Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging

Available to Purchase
Sen Zhang, Charles E. Ayemoba, Anna M. Di Staulo, Kenneth Joves, Chandani M. Patel, Eva Hin Wa Leung, Maura Lima Pereira Bueno, Xiaoping Du, Mortimer Poncz, Sang-Ging Ong, Claus Nerlov, Maria Maryanovich, Constantinos Chronis, Sandra Pinho
Journal: Blood
Blood blood.2024027432.
https://doi.org/10.1182/blood.2024027432
Published: 2025
Includes: Supplemental data
Journal Articles

An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis

Available to Purchase
Justin Loke, Peter G. Kim, Thuy T. P. Nguyen, Meaghan Boileau, Marie McConkey, Aidan Miller, Wesley Shin, Christopher B. Hergott, Maria Ericsson, Anja Nordstrom, Paula Montero Llopis, Scott A. Armstrong, Joseph D. Mancias, Benjamin L. Ebert
Journal: Blood
Blood (2025) 146 (10): 1174–1186.
https://doi.org/10.1182/blood.2024028033
Published: 2025
Includes: Supplemental data
Journal Articles

Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Available to Purchase
Dejene Milkessa Tufa, Eric Hoffmeyer, Kristin L Schaller, Ben Kooiman, Elena Woods, Dong Wang, Dallas Clinton Jones, Spencer C Hall, Joselyn Cruz Cruz, Michael Vernaris
Journal: Blood
Blood blood.2025028504.
https://doi.org/10.1182/blood.2025028504
Published: 2025
Includes: Supplemental data
Journal Articles

Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Open Access
Clinical Trials & Observations
Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Nösslinger, Julia von Tresckow, Rüdiger Liersch, Tobias Gaska, Kathleen Jentsch-Ulrich, Michael Gärtner, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Ursula Vehling-Kaiser, Matthias Ritgen, Christian Spoer, Michael J. Eckart, Thomas Decker, Geothy Chakupurakal, Björn Schöttker, Jens Kisro, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Janina Stumpf, Anna Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael J Hallek, Barbara F. Eichhorst
Journal: Blood
Blood blood.2025028550.
https://doi.org/10.1182/blood.2025028550
Published: 2025
Includes: Supplemental data
Journal Articles

Platelet heterogeneity in disease: the many and the diverse?

Open Access
Rainer Kaiser, Afra Anjum, Leo Nicolai
Journal: Blood
Blood blood.2025028957.
https://doi.org/10.1182/blood.2025028957
Published: 2025
Journal Articles

A bispecific nanobody for the treatment of von Willebrand disease type 1

Available to Purchase
Ivan Peyron, Caterina Casari, Genevieve McCluskey, Stéphanie Roullet, Vincent N Licari, Emilie Bocquet, Claire Auditeau, Melanie Y Daniel, Sophie Susen, Olivier D. Christophe, Peter J Lenting, Cécile V. Denis
Journal: Blood
Blood blood.2025029401.
https://doi.org/10.1182/blood.2025029401
Published: 2025
Includes: Supplemental data
Images
A UMI-barcoded in vivo CRISPR-Cas9 screen identifies synthetic lethal targets of Tet2 KO–driven expansion of HSPCs. (A) A nucleotide-encoded UMI linked to an sgRNA expression cassette in a lentiviral vector allows clonal tracing after transduction. Lentiviral infection of WT or Tet2 KO Cas9 expressing murine LSK HSPCs was harvested 14 weeks after transplantation into lethally IR recipients. (B) Analysis strategy to identify genetic dependencies of Tet2 KO HSPC growth after UMI-based in vivo screening. (C-D) Results of the pooled CRISPR-Cas9 KO screen in Tet2 KO and WT HSPCs. (C) Candidate genes result in a reduced number of Tet2 KO clones compared with WT. P value was obtained using a Fisher exact test comparing the number of clones containing nontargeting sgRNAs with the number of clones containing gene-specific sgRNAs in WT vs Tet2 KO. (D) Genes with greater persisting clones in WT (Tet2 KO–WT clone numbers >50) were subsequently ranked by Tet2 KO–specific decrease in clone size (variant allelic frequency [VAF]) at 14 weeks, and VAF differences were assessed by Welch’s t test. Row normalized by z score. All P values were adjusted for multiple hypothesis testing via FDR. (E) VAF and (F) clone numbers for the top Tet2 KO–specific target genes identified in the CRISPR-Cas9 screen. Welch’s t test: n.s., ∗P < .01; ∗∗P < .001; ∗∗∗P < .0001. FDR, false discovery rate; IR, irradiated; LTR, long-terminal repeat; n.s., nonsignificant.

A UMI-barcoded in vivo CRISPR-Cas9 screen identifies synthetic lethal targe...

Available to Purchase
in An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis > Blood
Published: 2025
Figure 1. A UMI-barcoded in vivo CRISPR-Cas9 screen identifies synthetic lethal targets of Tet2 KO–driven expansion of HSPCs. (A) A nucleotide-encoded UMI linked to an sgRNA expression cassette in a lentiviral vector allows clonal tracing after transduction. Lentiviral infection of WT or Tet2... More about this image found in A UMI-barcoded in vivo CRISPR-Cas9 screen identifies synthetic lethal targe...
Images
Ncoa4 KO impairs Tet2 KO competitive advantage in mouse transplant models. (A) Competitive transplantation of Cas9 expressing WT or Tet2 KO HSCs (CD150+CD135−CD48−lineage−Sca1+Kit+) transduced with sgRNA targeting Ncoa4 (sgNcoa4) or sgRNA nontargeting control (sgNTG). Lentiviral vector expresses a fluorescent protein, enabling tracing of transduced hematopoietic progeny. (B) Serial peripheral blood flow cytometric analysis after transplantation of WT or Tet2 KO cells containing blue fluorescent protein–labeled sgNTG or red fluorescent protein–labeled sgNcoa4. Results were normalized to the percentage of blue fluorescent protein–labeled cells expressing sgNTG. Significance test by 2-way ANOVA. Bars showing mean with standard error of the mean (SEM). N = 9 to 10 mice per arm. (C) Competition experiment between Vav-Cre+;Cd45.1/2 control cells and either Tet2 fl/fl Vav-Cre+;Cd45.2 (Tet2 KO), Ncoa4 fl/fl Vav-Cre+;Cd45.2 (Ncoa4 KO), Tet2 fl/fl Ncoa4 fl/fl Vav-Cre+Cd45.2 (Tet2 KO Ncoa4 KO), or WT Vav-Cre+;Cd45.2 BM cells transplanted at an 80:20 (WT-to-competitor) ratio, injected into lethally IR Cd45.1 recipients. (D) CD45.2 chimerism analysis from peripheral blood at each time point, as a percentage of total donor (CD45.2 and CD45.1/CD45.2) in mice transplanted with Vav-Cre transgenic mice as per panel C. Bars showing mean with SEM. N = 18 to 20 mice per arm. Unpaired t test between Tet2 KO and Tet2 KO Ncoa4 KO. ∗P < .01; ∗∗P < .001. (E) Transplant of whole BM from primary Vav-Cre transgenic mice (from panel C) into secondary recipients. Peripheral blood analysis of whole BM based on CD45 chimerism. Bars showing mean with SEM. N = 5 mice per arm. (F) Competition experiment between Mx-Cre+;Cd45.1/2 control and either Tet2 fl/fl Mx-Cre+;Cd45.2 (Tet2 KO), Ncoa4 fl/fl Mx-Cre+;Cd45.2 (Ncoa4 KO), Tet2 fl/fl Ncoa4 fl/fl Mx-Cre+Cd45.2 (Tet2 KO Ncoa4 KO), or WT Mx-Cre+;Cd45.2 BM cells. BM transplanted at an 80:20 (WT-to-competitor) ratio into lethally IR Cd45.1 recipients. pIpC injections 10 mg/kg intraperitoneally on alternate days for 3 doses. (G) CD45.2 chimerism analysis from peripheral blood at each time point, as a percentage of total donor (CD45.2 and CD45.1/CD45.2) from panel F. Bars showing mean with SEM. N = 17 to 20 mice per arm. Unpaired t test between Tet2 fl/fl and Tet2 fl/fl; Ncoa4 fl/fl. Dashed line demarcates the start of pIpC injections. (H) CD45 chimerism in lineage negative, LK, LSK, and CD150+CD48−LSK (HSC) BM fractions from Mx-Cre transgenic mice from panel F at 11 weeks after transplant. N = 9 to 10 mice per arm. Unpaired t test between genotypes indicated. (I) Flow cytometric analysis of HSC and multipotent progenitor BM populations from mice transplanted with Cas9-expressing WT or Tet2 KO HSCs infected with either sgNcoa4 or sgNTG. Results were normalized to the percentage of cells expressing sgNTG. The flow gating strategy is depicted in supplemental Figure 2F. Unpaired t test, bars showing mean with SEM. Each point represents an individual mouse. N = 7 to 10 mice per arm. (J) Pseudotime trajectory of WT or Tet2 KO Cas9 LSK HSPCs transduced with control or Ncoa4 gRNAs. Analysis was performed using Monocle3.36 Pseudotime trajectory annotation with expression of stem and HSPC markers is highlighted in supplemental Figure 2K. (K) Using cell clusters at the top of the pseudotime trajectory (blue label), which excludes differentiated Fcgcr3+ progenitors, gene set enrichment analysis was performed using all of the C2 Molecular Signatures Database.37Tet2 KO HSPCs transduced with control nontargeting gRNAs were compared with Tet2 KO HSPCs transduced with Ncoa4 gRNAs (gNcoa4). This revealed enrichment of gene sets expressed in stem cell (red) and leukemia (orange) signatures. (L) Highlighted HSPC gene sets enriched in sgNTG compared with sgNcoa4 transduced Tet2 KO HSPCs. ANOVA, analysis of variance; IR, irradiated; LK, lineage−cKit+; pIpC, polyinosinic:polycytidylic acid.

Ncoa4 KO impairs Tet2 KO competitive advantage in mouse transplant model...

Available to Purchase
in An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis > Blood
Published: 2025
Figure 2. Ncoa4 KO impairs Tet2 KO competitive advantage in mouse transplant models. (A) Competitive transplantation of Cas9 expressing WT or Tet2 KO HSCs (CD150 + CD135 − CD48 − lineage − Sca1 + Kit + ) transduced with sgRNA targeting Ncoa4 (sgNcoa4) or sgRNA nontargeting control (sgNTG... More about this image found in Ncoa4 KO impairs Tet2 KO competitive advantage in mouse transplant model...
Images
Expansion of Tet2 KO HSPCs is dependent on lysosome-dependent ferritinophagy. (A) Tet2 fl/fl; Vav-Cre+ (Tet2 KO) compared with Vav-Cre+ (WT) Hoxb8-ER immortalized HSPC have increased growth after 4 days in RPMI + 10% FCS, but not in 1% FCS unless supplemented with FAC (100 μM). N = 6. (B) Immunoblot of WT and Tet2 KO Hoxb8-ER HSPC treated with DFO 50 μM and/or E64D lysosomal protease inhibitor 2 μg/mL for 16 hours. Immunoblot with FTH1 and β-actin antibody. Dashed line, total FTH1 protein; solid line, lysosomal degraded FTH1 product.47 Fold-change quantification of lysosomal degraded FTH1 product, normalized to β-actin and untreated WT cells. N = 3. (C) Cytoplasmic Fe2+ pool in HSC from Tet2 KO compared with WT. Median fluorescent intensity of labile iron stain relative to untreated WT. Cells were treated with either DFO at 50 μM or vehicle control during concurrent staining to demonstrate the specificity of the labile iron stain. Each dot represents an individual mouse. Gating strategy as per supplemental Figure 2F. Representative flow cytometry histogram of HSCs from WT or Tet2 KO mice. N = 7. (D) Schematic of a competition experiment between WT or Tet2 KO CD45.2+ (20% composition) and WT CD45.1+/CD45.2+ control (80% composition) BM cells transplanted into lethally IR CD45.1 recipients. After engraftment at 4 weeks, mice were treated with a 4-week treatment of ironomycin (3 mg/kg intraperitoneally 5 days/wk) vs vehicle before harvest for peripheral blood and BM. (E) Peripheral blood analysis of whole blood and CD11b compartments and (F) BM analysis of CD45.2+Tet2 KO and CD45.1+/CD45.2+ WT donor chimerism after a 4-week treatment of either ironomycin or vehicle control. Each point represents an individual mouse. N = 12 to 15 per arm. Bars show mean with SEM, with unpaired t test used unless otherwise specified. CMP, common myeloid progenitor; DFO, deferoxamine; FAC, ferric ammonium citrate; FCS, fetal calf serum; GMP, granulocyte-monocyte progenitor; IR, irradiated; MEP, megakaryocyte-erythroid progenitor.

Expansion of Tet2 KO HSPCs is dependent on lysosome-dependent ferritinoph...

Available to Purchase
in An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis > Blood
Published: 2025
Figure 3. Expansion of Tet2 KO HSPCs is dependent on lysosome-dependent ferritinophagy. (A) Tet2 fl/fl; Vav-Cre + ( Tet2 KO) compared with Vav-Cre + (WT) Hoxb8-ER immortalized HSPC have increased growth after 4 days in RPMI + 10% FCS, but not in 1% FCS unless supplemented with FAC (100 μM... More about this image found in Expansion of Tet2 KO HSPCs is dependent on lysosome-dependent ferritinoph...
Images
Increased mitochondrial ATP production in Tet2 KO HSPCs is dependent on ferritinophagy. (A) Using cell clusters at the top of the pseudotime trajectory (blue label) (from Figure 2J), which excludes Fcgcr3+ differentiated progenitors, gene set enrichment analysis was performed comparing WT with Tet2 KO HSPCs using all of the C2 Molecular Signatures Database.37 This revealed enrichment of gene sets involved in mitochondrial function (purple) and oxidative phosphorylation (green). (B) Highlighted mitochondrial and oxidative phosphorylation gene sets comparing WT with Tet2 KO HSPCs. (C) Targeted CRISPR screen using mitochondrial and iron homeostasis regulatory genes in WT and Tet2 KO Cas9 LSK HSPCs. Tet2 KO HSPCs exhibit genetic dependency on regulators of iron, mitochondrial respiration, and translation. Highlighted genes have a false discovery rate of <0.25, WT/Tet2 KO persisting clone differences of >2, and WT/Tet2 KO VAF of >1. (D) Doxycycline-inducible Cas9 expressing WT or Tet2 fl/fl Vav1-Cre (Tet2 KO) in Hoxb8 HSPC system transduced with either control sgRNA (NTG) or Steap3 targeting sgRNA (sg1 and sg2) or Idh3g targeting sgRNA (sg1 and sg2). Growth relative to no doxycycline-treated cells at 4 days. N = 5. Bars showing mean ± SEM, unpaired t test. (E) Transmission electron microscopy (TEM) of primary WT and Tet2 KO LSK HSPCs. Cristae number normalized to the length of mitochondria. Scale bar, 500 nm. N = 50 to 57 mitochondria from 5 mice per genotype. Mean and SEM are displayed with results of unpaired t test. (F) TEM of WT and Tet2 KO Hoxb8 with control short hairpin RNA (shRNA), Ncoa4 shRNA, or ironomycin treatment 50 nM for 48 hours. Images in supplemental Figure 4B. Cristae number was normalized to the length of mitochondria. N = 30 to 71 mitochondria per experimental condition. Mean and SEM are displayed with results of unpaired t test. (G) Mitochondrial staining of primary WT and Tet2 KO CD135−CD48−CD34−CD150+ HSCs. Scale bar, 5 μm. Representative slice from a 3-dimensional structured illumination microscopy image shown. Quantification of mean volume divided by counted mitochondria. Bars showing mean ± SEM, with unpaired t test. Each dot represents an analysis of an individual cell from 5 mice per genotype. (H) Representative Seahorse Mito Stress assay of WT and Tet2 KO Hoxb8-ER cells treated with either vehicle (dimethyl sulfoxide [DMSO]) or ironomycin (50 nM) for 48 hours. Quantification of mitochondrial and glycolytic ATP production is shown in supplemental Figure 4D. (I) Primary human CD34+ umbilical cord HSPCs were transfected with either AAVS1 or TET2 (sg1 and sg2) gRNA–CRISPR-Cas9 RNP complexes. Adenovirus encoding mNeonGreen sequence with adjoining DNA sequence homologous to edited loci results in integration at targeted genes. Fluorescent activated cell sorting (FACS) was used to purify successfully edited cells identified via mNeonGreen expression. Purified cells were analyzed with the Seahorse Mito Stress assay. The mitochondrial ATP production rate is derived from OCR and extracellular acidification rate. N = 7. (J) Seahorse Mito Stress assay on primary human CD34 HSPCs transfected with either AAVS1 or TET2 targeting gRNA were treated with either DMSO (vehicle) or ironomycin 200 nM for 48 hours. Quantification of mitochondrial ATP production was summarized from Seahorse assays. N = 2-6. Mean and SEM are displayed with results of unpaired t test. AMA/Rot, antimycin A/rotenone; FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; KI, knockin; OCR, oxygen consumption rate; Oligo, oligomycin; RNP, ribonucleoprotein.

Increased mitochondrial ATP production in Tet2 KO HSPCs is dependent on f...

Available to Purchase
in An in vivo barcoded CRISPR-Cas9 screen identifies Ncoa4- mediated ferritinophagy as a dependence in Tet2 -deficient hematopoiesis > Blood
Published: 2025
Figure 4. Increased mitochondrial ATP production in Tet2 KO HSPCs is dependent on ferritinophagy. (A) Using cell clusters at the top of the pseudotime trajectory (blue label) (from Figure 2 J), which excludes Fcgcr3 + differentiated progenitors, gene set enrichment analysis was performed com... More about this image found in Increased mitochondrial ATP production in Tet2 KO HSPCs is dependent on f...
Journal Articles

A multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes

Available to Purchase
Dylan C. Gagler, Hussein Ghamlouch, Di Zhang, Patrick Blaney, Avital Tenenbaum, James Langton, Marine Armand, Alexandre Eeckhoutte, Amina Joudat, Michaël Degaud, Michela Esposito, Gaurav Varma, Yubao Wang, Sanghoon Lee, Sanxiong Liu, Oscar Lahoud, David Kaminetzky, Marc Braunstein, Louis Williams, Florence Nguyen-Khac, Brian Walker, Damien Roos-Weil, Faith E. Davies, Olivier A. Bernard, Gareth J. Morgan
Journal: Blood
Blood (2025) 146 (10): 1225–1238.
https://doi.org/10.1182/blood.2024028164
Published: 2025
Includes: Supplemental data
Journal Articles

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA

Available to Purchase
Clinical Trials & Observations
Maria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, Matin Salehi, Federico Jauk, Gabriela Forestieri, Simone Bocchetta, Deborah Piffaretti, Riccardo Moia, Vanessa Cristaldi, Martina di Trani, Georgia Alice Galimberti, Katia Pini, Valeria Spina, Claudia Giordano, Adalgisa Condoluci, Ilaria Romano, Salvatore Annunziata, Fabrizio Bergesio, Renzo Boldorini, Eugenio Borsatti, Pietro Bulian, Eleonora Calabretta, Stephane Chauvie, Francesco Corrado, Stefania Crisci, Marco Cuzzocrea, Rosaria De Filippi, Bernhard Gerber, Michał Kurlapski, Luigi Maria Larocca, Elisabetta Merlo, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Anastasios Stathis, Georg Stüssi, Ilaria Zangrilli, Antonello Pinto, Luca Mazzucchelli, Valter Gattei, Jan Maciej Zaucha, Armando Santoro, Stefan Hohaus, Franco Cavalli, Alexandar Tzankov, Carmelo Carlo-Stella, Gianluca Gaidano, Luca Ceriani, Emanuele Zucca, Davide Rossi
Journal: Blood
Blood (2025) 146 (10): 1207–1224.
https://doi.org/10.1182/blood.2024027355
Published: 2025
Includes: Supplemental data
Journal Articles

RhoA GAP Myo9b regulates β 2 -integrin activity and neutrophil recruitment during murine acute kidney injury

Available to Purchase
Anika Cappenberg, Marina Oguama, Mathis Richter, Andreas Margraf, Wida Amini, Pia Lindental, Sina Mersmann, Bernadette Bardel, Helena Block, Thomas Vogl, Oliver Soehnlein, Klaus Ley, Jan Rossaint, Alexander Zarbock
Journal: Blood
Blood (2025) 146 (10): 1194–1206.
https://doi.org/10.1182/blood.2024027583
Published: 2025
Includes: Multimedia, Supplemental data
Journal Articles

Clinical and molecular features of immunodeficiency in patients with telomere biology disorders

Available to Purchase
Clinical Trials & Observations Brief Report
Luiz Fernando Bazzo Catto, Nidhi Aggarwal, Ruba Shalhoub, Xiaoyang Ma, Ivana Darden, Tania Machado, Yue Zhang, Neelam R. Redekar, Natthakan Thongon, Simona Colla, Geraldine Aubert, Cynthia E. Dunbar, Colin O. Wu, Neal S. Young, Bhavisha A. Patel, Fernanda Gutierrez-Rodrigues, Emma M. Groarke
Journal: Blood
Blood (2025) 146 (10): 1187–1193.
https://doi.org/10.1182/blood.2024026735
Published: 2025
Includes: Supplemental data
Journal Articles

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1 -mutant AML

Free
Aristi Damaskou, Rachael Wilson, Malgorzata Gozdecka, George Giotopoulos, Ryan Asby, Maria Eleftheriou, Muxin Gu, Christian Récher, Véronique Mansat-De Mas, Francois Vergez, Ambrine Sahal, Binje Vick, Evangelia K. Papachristou, Ashley Sawle, Eliza Yankova, Monika Dudek, Xiaoxuan Liu, James Russell, Justyna Rak, Christine Hilcenko, Clive D’Santos, Irmela Jeremias, Jean-Emmanuel Sarry, Konstantinos Tzelepis, Brian J. P. Huntly, Alan J. Warren, Omid Tavana, George S. Vassiliou
Journal: Blood
Blood (2025) 146 (10): 1239–1252.
https://doi.org/10.1182/blood.2024026113
Published: 2025
Includes: Supplemental data